Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Português
English
Русский
中文
Español
日本語
Deutsch
한국어
Français
Italiano
Türkçe
SNDX
#1700
Syndax Pharmaceuticals, Inc.
21.7
1
+6.89%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+6.89%
Mudança mensal
+1.92%
Mudança em 6 meses
+32.54%
Mudança anual
+43.02%
Fechamento anterior
20.3
1
Open
21.7
1
Bid
Ask
Low
21.7
1
High
21.7
1
Volume
124
Mercados
Ações
Cuidados de saúde
SNDX
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
48.24 M
55.01 M
68.44 K
84.97 M
86.02 M
88.2 M
—
Valuation ratios
Enterprise value
957.52 M
982.25 M
-72.6 M
1.56 B
983.16 M
1.72 B
4.54 B
Price to earnings ratio
—
47.59
-10.41
-7.34
-3.55
-6.39
-16.26
Price to sales ratio
—
8.4
—
—
47.8
—
—
Price to cash flow ratio
—
40.29
-11.64
-9.58
-4.12
5.64
-4.96
Price to book ratio
—
2.87
3.33
2.78
3.93
28.16
31.45
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.24
0.06
0.3
0.34
0.44
0.54
0.49
Return on equity %
0.29
0.06
0.32
0.38
1.11
4.42
2.43
Return on invested capital %
2 493.6
929.46
4 423.93
2 612.85
1 177.24
746.06
792.31
Gross margin %
100
100
—
—
100
97.87
400
Operating margin %
4 708.17
18.77
—
—
1 434.43
158.45
817.14
EBITDA margin %
—
—
—
—
—
-163.2
—
Net margin %
4 822.54
17.84
—
—
1 346.11
165.6
844.3
Liquidity ratios
Quick ratio
—
—
—
—
5.82
4.12
18.85
Current ratio
15.84
21.68
16.85
10
5.82
4.4
19.55
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.01
0.37
0
0
0.04
0.27
0.3
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
0.06
0.04
0
—
0.46
-0.01
-0.04
Long term debt to total equity ratio
0.07
0.05
0
—
1.15
-0.09
-0.21
Per share metrics
Operating cash flow per share
—
0.54
2.2
2.28
3.21
3.73
3.74
EBIT per share
—
—
—
—
—
-3.19
—
EBITDA per share
—
—
—
—
—
-3.25
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
8.2
7.83
8.11
6.69
4.55
20.8
Net current asset value per share
—
8.36
8.06
8.25
7.04
6.1
24.74
Tangible book value per share
—
7.62
7.69
7.88
3.37
0.75
6.4
Working capital per share
—
7.98
7.58
7.43
5.83
4.71
19.63
Book value per share
—
7.62
7.69
7.88
3.37
0.75
6.4
Notícias
Stifel eleva preço-alvo da Syndax Pharmaceuticals com base nas vendas de medicamentos
Stifel raises Syndax Pharmaceuticals stock price target on drug sales
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript
Syndax reporta crescimento de 50% na receita do 4º tri de 2025 e traça caminho para lucratividade
Syndax Q4 2025 slides: revenue surges 50%, profitability path outlined
Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates
Lucro da Syndax Pharmaceuticals veio abaixo das projeções por $0,19; receita supera estimativas
Syndax Pharmaceuticals earnings missed by $0.19, revenue topped estimates
Syndax enfrenta teste de resultados enquanto lançamentos de medicamentos oncológicos aceleram
Syndax faces earnings test as cancer drug launches accelerate
Syndax na Cúpula Guggenheim: Forte crescimento e expansão estratégica
Syndax Pharmaceuticals' Early Launch Success Signals Continued Growth Into 2026 (NASDAQ:SNDX)